Market Cap: $374.83M
NI
Neurogene Inc.
NGNE
NASDAQ (NASDAQ Global Market)USD
Market Cap: $374.83M
Neoleukin Therapeutics: Pioneering Developments in Immune-Oncology In recent days, Neoleukin Therapeutics stands poised at the forefront of innovation within the immune-oncology sector, particularly t…
Navigating Regulatory Milestones: uniQure's Huntington's Disease Gene Therapy In a significant development for the field of gene therapy, uniQure N.V. receives crucial feedback from the U.S. Food and…
Neoleukin Therapeutics: Advancing Gene Therapy for Neurodegenerative Diseases Neoleukin Therapeutics is part of a rapidly evolving landscape in the biopharmaceutical sector, particularly in the realm…
Please provide the content you would like me to summarize, and I'll be happy to assist!
FDA's New Rare Disease Evidence Principles: A Game Changer for Therapeutics On Thursday, the U.S. Food and Drug Administration (FDA) unveils its Rare Disease Evidence Principles (RDEP), a groundbreaki…
FDA's New Framework Signals Progress for Rare Disease Therapies In a significant development for companies like Neoleukin Therapeutics, the U.S. Food and Drug Administration (FDA) announces the implem…
FDA Implements Rare Disease Evidence Principles to Streamline Therapy Development In a significant move to enhance the development of therapies for rare diseases, the U.S. Food and Drug Administration…
FDA Leadership Shake-Up Raises Concerns for Biologics Regulation In a notable development within the U.S. Food and Drug Administration (FDA), the recent resignation of Vinay Prasad as director of the…
Neurogene Inc. Navigates Challenges in Rett Syndrome Gene Therapy Trial Neurogene Inc., a clinical-stage biotechnology company, focuses on developing genetic therapies for rare neurological diseases.…
Neurogene’s NGN-401 Shows Promise in Rett Syndrome Treatment Neurogene Inc., a clinical-stage biotechnology firm dedicated to developing genetic therapies for rare neurological disorders, recently ann…